4.1 Signals of adverse events We observed that metabolic and nutritional adverse reactions were more frequently reported by females (Table 1), which has previously been interpreted as a greater inclination for females to report AEs to FAERS ( Exenatide (n = 10,450), dulaglutide (n = 4,847), liraglutide (n = 2,860), semaglutide (n = 2,905), and tirzepatide (n = 1,089) had the greatest number of reported AEs, and the highest number of AEs reported on the effects of appetite, as reflected in our analyses of the HLT stratum (Supplementary Table S2)
What distinguishes NOW Foods from other large supplement brands
Certain peptides like PT-141 work differently based on sex
Use sunscreen when applying during the daytime AI-generated from the product information
The STEP trials evaluating semaglutide 2.4 mg for weight management reported gallbladder disorders in approximately 1.6-2.6% of participants receiving the medication versus 0.7-1.2% receiving placebo
Integrated network pharmacology analysis and experimental validation to elucidate the mechanism of acteoside in treating diabetic kidney disease